95 related articles for article (PubMed ID: 33203095)
1. Periostin and Thymic Stromal Lymphopoietin-Potential Crosstalk in Obstructive Airway Diseases.
Nejman-Gryz P; Górska K; Paplińska-Goryca M; Proboszcz M; Krenke R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33203095
[TBL] [Abstract][Full Text] [Related]
2. Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation.
Andreasson LM; Dyhre-Petersen N; Hvidtfeldt M; Jørgensen GØ; Von Bülow A; Klein DK; Uller L; Erjefält J; Porsbjerg C; Sverrild A
J Allergy Clin Immunol; 2024 Apr; 153(4):988-997.e11. PubMed ID: 38081546
[TBL] [Abstract][Full Text] [Related]
3. Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma.
Türk M; Yilmaz I; Gökahmetoğlu S; Koç AN
Turk J Med Sci; 2021 Jun; ():. PubMed ID: 34118804
[TBL] [Abstract][Full Text] [Related]
4. Exploring TSLP and IL-33 Serum Levels and Genetic Variants: Unveiling Their Limited Potential as Biomarkers for Mild Asthma in Children.
Połomska J; Sikorska-Szaflik H; Drabik-Chamerska A; Sozańska B; Dębińska A
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731070
[TBL] [Abstract][Full Text] [Related]
5. Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases.
Adhikary PP; Idowu T; Tan Z; Hoang C; Shanta S; Dumbani M; Mappalakayil L; Awasthi B; Bermudez M; Weiner J; Beule D; Wolber G; Page BD; Hedtrich S
EMBO Mol Med; 2024 Jun; ():. PubMed ID: 38877290
[TBL] [Abstract][Full Text] [Related]
6. Serum periostin levels in adults of Chinese descent: an observational study.
Tan E; Varughese R; Semprini R; Montgomery B; Holweg C; Olsson J; Caswell-Smith R; Fingleton J; Weatherall M; Beasley R; Braithwaite I
Allergy Asthma Clin Immunol; 2018; 14():87. PubMed ID: 30574168
[TBL] [Abstract][Full Text] [Related]
7. Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma.
Al-Shaikhly T; Murphy RC; Lai Y; Frevert CW; Debley JS; Ziegler SF; Wong K; Jia G; Holweg CTJ; Peters MC; Hallstrand TS
Respirology; 2023 May; 28(5):491-494. PubMed ID: 36914406
[No Abstract] [Full Text] [Related]
8. [Linear porokeratosis with severe itch accompanied by lesional upregulation of interleukin 31, thymic stromal lymphopoietin, and periostin].
Hashimoto T; Moriyama Y; Satoh T
Eur J Dermatol; 2021 Aug; 31(4):570-2. PubMed ID: 34463291
[No Abstract] [Full Text] [Related]
9. Response of sputum periostin to anti-T2 biologics treatment in severe asthma.
Nair P; Radford K; Nunomura S; Mukherjee M; Izuhara K
Allergy; 2024 Apr; ():. PubMed ID: 38651839
[No Abstract] [Full Text] [Related]
10. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma.
Chen M; Shepard K; Yang M; Raut P; Pazwash H; Holweg CTJ; Choo E
Clin Exp Allergy; 2021 Apr; 51(4):546-555. PubMed ID: 33217063
[TBL] [Abstract][Full Text] [Related]
11. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease.
Higham A; Beech A; Wolosianka S; Jackson N; Long G; Kolsum U; Southworth T; Pham TH; Sridhar S; McCrae C; Newbold P; Singh D
Allergy; 2021 Jun; 76(6):1861-1864. PubMed ID: 33206402
[No Abstract] [Full Text] [Related]
12. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.
Drick N; Milger K; Seeliger B; Fuge J; Korn S; Buhl R; Schuhmann M; Herth F; Kendziora B; Behr J; Kneidinger N; Bergmann KC; Taube C; Welte T; Suhling H
J Asthma Allergy; 2020; 13():605-614. PubMed ID: 33204117
[TBL] [Abstract][Full Text] [Related]
13. Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype.
Moermans C; Damas K; Guiot J; Njock MS; Corhay JL; Henket M; Schleich F; Louis R
Cytokine; 2021 Apr; 140():155421. PubMed ID: 33486314
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33 and thymic stromal lymphopoietin, but not interleukin-25, are crucial for development of airway eosinophilia induced by chitin.
Arae K; Ikutani M; Horiguchi K; Yamaguchi S; Okada Y; Sugiyama H; Orimo K; Morita H; Suto H; Okumura K; Taguchi H; Matsumoto K; Saito H; Sudo K; Nakae S
Sci Rep; 2021 Mar; 11(1):5913. PubMed ID: 33723298
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A
Emson C; Corren J; Sałapa K; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():91-99. PubMed ID: 33568920
[TBL] [Abstract][Full Text] [Related]
16. Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation.
Delgado-Eckert E; James A; Meier-Girard D; Kupczyk M; Andersson LI; Bossios A; Mikus M; Ono J; Izuhara K; Middelveld R; Dahlén B; Gaga M; Siafakas NM; Papi A; Beghe B; Joos G; Rabe KF; Sterk PJ; Bel EH; Johnston SL; Chanez P; Gjomarkaj M; Howarth PH; Niżankowska-Mogilnicka E; Dahlén SE; Frey U
J Allergy Clin Immunol; 2021 Aug; 148(2):407-419. PubMed ID: 33548398
[TBL] [Abstract][Full Text] [Related]
17. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of thymus and activation-regulated chemokine and of periostin in eosinophilic asthma: A prospective study.
Yormaz B; Menevse E; Cetin N; Celik ZE; Bakir H; Tulek B; Korez MK; Suerdem M
Allergy Asthma Proc; 2020 Nov; ():. PubMed ID: 33228831
[TBL] [Abstract][Full Text] [Related]
19. A shotgun proteomic approach reveals novel potential salivary protein biomarkers for asthma.
Poachanukoon O; Roytrakul S; Koontongkaew S
J Asthma; 2022 Feb; 59(2):243-254. PubMed ID: 33211619
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
